Use of CAR T-Cell Therapy in LBCL Could Come Earlier After ASH 2021
AJMC,
Some of the most anticipated presentations at the 63rd Annual American Society of Hematology (ASH) Meeting and Exposition…
POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.
Overview of attention for article published in Journal of Clinical Oncology, May 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (80th percentile)
-
Good Attention Score compared to outputs of the same age and source (70th percentile)
Readers on
- mendeley
- 18 Mendeley